News

The MISHC paper, “Quality of Life After Mitral Transcatheter Edge-to-Edge Repair According to Baseline Tricuspid Regurgitation,” was published in Structural Heart.

There is a high prevalence of significant tricuspid regurgitation (TR) in patients undergoing mitral transcatheter edge-to-edge repair (M-TEER).

Significant tricuspid regurgitation is associated with poor prognosis and affects decision-making between M-TEER and concomitant mitral and tricuspid valve surgery. Improved quality of life (QoL) is an important metric for patients.

Collin J. Brooks, MD, and colleagues reviewed MISHC data from 1838 patients undergoing M-TEER from 2015 to 2023. QoL was assessed using baseline and 30-day Kansas City Cardiomyopathy Questionnaire (KCCQ) scores.

Patients were classified as no/mild TR or moderate/severe TR, and changes in KCCQ scores were compared. The primary outcome was an adjusted analysis consisting of survival to 30 days with a ≥15-point improvement in KCCQ score.

On average, patients undergoing M-TEER experienced large improvements in QoL, regardless of baseline TR group.

Patients with moderate/severe TR exhibited no difference in the primary adjusted outcome.

The majority of patients experience a large improvement in QoL after M-TEER, regardless of baseline TR severity. Further research should explore a staged approach of M-TEER followed by tricuspid valve intervention as needed, compared to concomitant mitral/tricuspid valve surgery.

Co-authors are Neal Duggal, MD; Milan Seth, MS; Megan S. Joseph, MD; Devraj Sukul, MD, MSc; Stan J. Chetcuti, MD; Gorav Ailawadi, MD; Himanshu Patel, MD; P. Michael Grossman, MD; Raed Alnajjar, MD; and Andrew W. Harris, MD

Read the entire publication in Structural Heart.